Skip to main content

Table 1 Basic information of subjects enrolled in the group

From: A study on the pharmacokinetic bioequivalence of oral tablet formulations of riluzole among healthy volunteers utilizing HPLC-MS/MS

Indicator

 

T-R N(%)

R-T N(%)

Total N(%)

Age (one year old)

Mean ± Sd

29 ± 8

28 ± 8

29 ± 8

M(Q1 ~ Q3)

29(24 ~ 31)

27(21 ~ 32)

27(23 ~ 32)

Min ~ Max

18 ~ 49

19 ~ 50

18 ~ 50

Age group N (%)

< 18

0(0.0)

0(0.0)

0(0.0)

18–40

31(86.1)

32(88.9)

63(87.5)

41–60

5(13.9)

4(11.1)

9(12.5)

> 60

0(0.0)

0(0.0)

0(0.0)

Total

36(100.0)

36(100.0)

72(100.0)

Gender N (%)

Male

32(88.9)

33(91.7)

65(90.3)

Famle

4(11.1)

3(8.3)

7(9.7)

Total

36(100.0)

36(100.0)

72(100.0)

Ethnic N (%)

Han ethnic group

33(91.7)

33(91.7)

66(91.7)

Others

3(8.3)

3(8.3)

6(8.3)

Total

36(100.0)

36(100.0)

72(100.0)

Height (cm)

Mean ± Sd

168.6 ± 8.4

169.8 ± 8.8

169.2 ± 8.6

M(Q1 ~ Q3)

169.8(164.3 ~ 173.0)

169.3(164.3 ~ 175.8)

169.5(164.3 ~ 174.3)

Min ~ Max

146.5 ~ 185.0

150.5 ~ 189.5

146.5 ~ 189.5

Body weight (kg)

Mean ± Sd

63.4 ± 7.0

63.7 ± 6.9

63.5 ± 6.9

M(Q1 ~ Q3)

63.1(58.8 ~ 69.3)

63.3(58.0 ~ 70.3)

63.2(58.4 ~ 69.5)

Min ~ Max

45.9 ~ 75.6

53.4 ~ 80.1

45.9 ~ 80.1

BMI(kg/m2)

Mean ± Sd

22.3 ± 1.6

22.1 ± 1.8

22.2 ± 1.7

M(Q1 ~ Q3)

21.9(21.2 ~ 23.3)

21.7(20.9 ~ 24.1)

21.9(21.0 ~ 23.6)

Min ~ Max

19.6 ~ 25.7

19.5 ~ 25.4

19.5 ~ 25.7

  1. Mean ± Sd, Mean ± standard deviation; M(Q1 ~ Q3), combination of median and interquartile range; Min, the minimum value; Max, the maximum value; T, test preparation; R, reference preparation; BMI, body mass index